Beone Medicines

This study tests whether a new drug called BGB-16673 works better than current standard treatments for people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to previous therapy. About 150 participants in China and Taiwan wh…

This study is testing if a stomach cancer drug called tislelizumab works just as well when given as a simple injection under the skin, compared to the standard method of a slow infusion into a vein. It will involve about 351 adults with advanced stomach cancer who have not yet re…

This is the first study in people to test a new potential cancer drug called BG-C477. The main goal is to find out if the drug is safe, what side effects it causes, and what dose to use. It will be tested alone and combined with other cancer treatments in adults with advanced sol…

This study is testing a new drug called sonrotoclax for people with multiple myeloma that has come back or stopped responding to other treatments. Researchers want to see if sonrotoclax is safe and effective when given alone or combined with other standard myeloma drugs. The tria…

This is the first human study of a new cancer drug called BGB-58067. Researchers are testing its safety and how the body processes it in people with advanced solid tumors that have a specific genetic feature (MTAP deficiency). The drug will be given alone and combined with other …

This is an early-stage study to find a safe dose for a new experimental drug called BGB-26808. It will be tested alone and in combination with an existing immunotherapy drug, tislelizumab, in adults with advanced solid tumors that have spread or cannot be removed by surgery. The …

This is an early-stage study to test the safety and initial effects of a new drug called BG-75098 for people with advanced solid tumors. The trial will first find a safe dose for the drug, given alone or with other cancer treatments. Researchers will also check if the drug shows …

This early-stage study is testing a new targeted cancer drug called BG-C9074, both alone and in combination with other cancer therapies. The trial aims to find safe doses and see if the drug helps control advanced solid tumors in people who have run out of standard treatment opti…

This is the first time researchers are testing the experimental drug BG-A3004 in people. The study aims to check if the drug is safe and how it behaves in the body, first in healthy volunteers and then in patients with immune-related skin conditions like alopecia areata, lichen p…

This study is testing a new oral medication called BGB-16673 for people with various B-cell cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe and effective dose and to see how well the drug shrinks tumors. It is for adults …

This early-stage study is testing whether new drug combinations are safe for people with advanced hormone-positive breast cancer that has spread. Researchers will give 120 participants either two or three drugs together to see how well they're tolerated and if they help shrink tu…

This is a first-in-human study to test the safety and find the right dose of a new experimental drug called BG-C0902 for people with advanced solid tumors. The drug is designed to target two specific proteins found on some cancer cells. Researchers will enroll about 63 participan…

This study is testing the safety and early effectiveness of a new drug, BGB-16673, when given with other cancer medicines. It is for people whose B-cell cancers, like certain lymphomas, have returned or stopped responding to previous treatments. The trial will test four different…

This is a first-in-human study to test the safety and initial effectiveness of a new drug called BGB-B2033. It will be given alone or in combination with other cancer drugs to people with specific advanced or metastatic solid tumors, including certain liver, lung, stomach, and ge…

This study is testing whether a new drug called sonrotoclax works better than the current standard treatment, venetoclax, for adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to previous therapies. About 630 participants w…

This study is testing a new drug called BGB-16673 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has come back or stopped responding after two common types of targeted therapies. About 250 participants worldwide will be randoml…

This study aims to see if adding a new drug called sonrotoclax to an existing drug (zanubrutinib) works better than zanubrutinib alone for adults whose mantle cell lymphoma has returned or stopped responding to prior treatments. It will involve about 300 participants and directly…

This study aims to see if a new investigational drug, BGB-16673, works better and is as safe as an existing drug, pirtobrutinib, for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to prior treatment. It will involv…

This early-stage study is testing a new targeted cancer drug called BG-C137 in people with advanced solid tumors that have specific genetic markers. The main goals are to determine safe dosage levels and see if the drug shows any signs of fighting the cancer. The trial will enrol…

This is an early-stage study to test the safety and initial effectiveness of a new oral drug called BG-75202. It will be given to people with advanced breast cancer and other solid tumors who have run out of standard treatment options. The study will first test the drug alone to …

This study aims to see if a new combination of drugs (sonrotoclax plus zanubrutinib) works better and is safer than a current standard combination (venetoclax plus acalabrutinib) for people newly diagnosed with chronic lymphocytic leukemia (CLL). It will involve about 500 adults …